A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture
about
The pyrazinamide susceptibility breakpoint above which combination therapy fails.Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Clinical evaluation of tuberculosis viability microscopy for assessing treatment response.Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human TuberculosisBacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High MortalityA multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.Pharmacologic considerations in use and development of antituberculosis drugs.Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB.The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes
P2860
Q34034401-99029976-6461-4CC7-B735-75527EC1AA50Q34922554-3536E6A9-929B-4F5F-A842-15CCD257DFCDQ35207458-41F7CFDB-18E6-4BE1-B096-75CC7D354F79Q35993510-735AB464-B282-497C-B1F0-D84C43499E4BQ36100081-B71CE75A-8630-48CE-9FB5-34CA53259245Q36540925-53956B38-D260-4427-A658-3C7D53E118C5Q36684146-B5319DE1-F209-4F73-A44D-7659C6413E2AQ37339276-1B8F0A52-91ED-4391-8E4D-E380EABDB2E2Q38221214-96CD0690-F964-4AF5-AF37-31313724F4CAQ38252559-41EC8A2F-32ED-4CCB-9053-060730C36DECQ41082086-860DED00-18FF-41C8-90CB-76E8E90BC64AQ47898423-4A134897-D05B-4115-AEA3-439C5AE65DA8Q57152709-96DEEFFD-0075-452A-AB12-8E8F09C44DC9
P2860
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A time-to-event pharmacodynami ...... d liquid mycobacterial culture
@ast
A time-to-event pharmacodynami ...... d liquid mycobacterial culture
@en
type
label
A time-to-event pharmacodynami ...... d liquid mycobacterial culture
@ast
A time-to-event pharmacodynami ...... d liquid mycobacterial culture
@en
prefLabel
A time-to-event pharmacodynami ...... d liquid mycobacterial culture
@ast
A time-to-event pharmacodynami ...... d liquid mycobacterial culture
@en
P2093
P2860
P50
P356
P1476
A time-to-event pharmacodynami ...... d liquid mycobacterial culture
@en
P2093
Emmanuel Chigutsa
Kashyap Patel
Marianne Visser
Mats O Karlsson
P2860
P304
P356
10.1128/AAC.01876-12
P407
P577
2012-11-26T00:00:00Z